Table 4:
Multivariable Cox Regression of Overall Survival with all Significant Geriatric Assessments
| Factor | Level | N | HR (95% CI) | P-Value |
|---|---|---|---|---|
| Age Group (years) | 65–69 | 142 | 1 (Reference) | 0.0293* |
| 70–74 | 115 | 1.629 (0.661, 4.015) | 0.2888 | |
| 75+ | 98 | 3.229 (1.337, 7.795) | 0.0092 | |
| Presence of del(17p13) | Normal | 324 | 1 (Reference) | |
| Abnormal | 31 | 3.527 (1.430, 8.698) | 0.0062 | |
| ECOG Performance Status | 0 | 187 | 1 (Reference) | |
| 1–2 | 168 | 0.369 (0.167, 0.814) | 0.0135 | |
| IADL - Activities of Daily Living subscale | =14 (Not Impaired) | 282 | 1 (Reference) | |
| <14 (Impaired) | 73 | 2.041 (0.911, 4.575) | 0.0831 | |
| Physician Reported Karnofsky Performance Status (Score 0–100) | 355 | 0.980 (0.932, 1.030) | 0.4218 | |
| Patient Reported Karnofsky Performance Status (Score 30–100) | 355 | 0.999 (0.960, 1.039) | 0.9524 | |
| Treatment Arm | Bendamustine + Rituximab | 110 | 1 (Reference) | 0.9319* |
| Ibrutinib | 122 | 1.151 (0.493, 2.684) | 0.7455 | |
| Ibrutinib + Rituximab | 123 | 1.160 (0.490, 2.747) | 0.7363 | |
| Rai Stage | Intermediate (Stage I/II) | 160 | 1 (Reference) | |
| High (Stage III/IV) | 195 | 0.822 (0.414, 1.630) | 0.5741 | |
| MOS - Social Activities Score | 355 | 0.978 (0.958, 0.999) | 0.0377 | |
| Sex | Male | 246 | 1 (Reference) | |
| Female | 109 | 0.704 (0.319, 1.557) | 0.3864 | |
| Percent Unintentional Weight Loss in last 6 months | < 5% (Not Impaired) | 281 | 1 (Reference) | |
| >= 5% (Impaired) | 74 | 1.795 (0.846, 3.807) | 0.1271 | |
| Zap70 Methylation Status | >=20% | 163 | 1 (Reference) | |
| <20% | 192 | 1.291 (0.636, 2.620) | 0.4798 |
*
overall p-value; ECOG=Eastern Cooperative Oncology Group, MOS=Medical Outcomes Study; IADL=Instrumental Activities of Daily Living
17 Patients were excluded from the final model due to missing values for one or more of the covariates